Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

##STR00001##

The present invention relates to a urea group containing product comprising one or more species of formula (I) R.sup.1—X—(C═O)—[NH—R.sup.2—NH—(C═O)—NH—R.sup.3—NH—(C═O)].sub.n—NH—R.sup.2—NH—(C═O)—X—R.sup.1 (I), 5 wherein R.sup.1 is independently selected from organic groups having (4) to (200) carbon atoms, X is O or NR.sup.4, wherein R.sup.4 is a hydrogen atom or an aliphatic or aromatic group having (1) to (30) carbon atoms, R.sup.2 is independently selected from hydrocarbyl groups having (4) to (40) carbon atoms, R.sup.3 is independently selected from hydrocarbyl groups having (2) to (40) carbon atoms, and wherein on average (76) to (100) mol % of all R.sup.3 groups contained in the one or more species of formula (I) are hydrocarbyl groups having (2) or (3) carbon atoms, and n is an integer of (2) to (150). The invention further relates to a method of manufacturing such urea group containing products, liquid compositions containing the same and the use of such liquid compositions as rheology control additives. Furthermore, the invention relates to a process for rheology adjustment adding such liquid composition to semi-finished or final products. The invention also relates to an article coated with the liquid composition.

The present invention relates to a urea group containing product comprising one or more species of formula (I) R.sup.1—X—(C═O)—[NH—R.sup.2—NH—(C═O)—NH—R.sup.3—NH—(C═O)].sub.n—NH—R.sup.2—NH—(C═O)—X—R.sup.1 (I), 5 wherein R.sup.1 is independently selected from organic groups having (4) to (200) carbon atoms, X is O or NR.sup.4, wherein R.sup.4 is a hydrogen atom or an aliphatic or aromatic group having (1) to (30) carbon atoms, R.sup.2 is independently selected from hydrocarbyl groups having (4) to (40) carbon atoms, R.sup.3 is independently selected from hydrocarbyl groups having (2) to (40) carbon atoms, and wherein on average (76) to (100) mol % of all R.sup.3 groups contained in the one or more species of formula (I) are hydrocarbyl groups having (2) or (3) carbon atoms, and n is an integer of (2) to (150). The invention further relates to a method of manufacturing such urea group containing products, liquid compositions containing the same and the use of such liquid compositions as rheology control additives. Furthermore, the invention relates to a process for rheology adjustment adding such liquid composition to semi-finished or final products. The invention also relates to an article coated with the liquid composition.

A method for producing a carbamic acid salt, including contacting a carbon dioxide-containing mixed gas having a partial pressure of carbon dioxide of 0.001 atm or more and less than 1 atm with an amino group-containing organic compound in the presence of a base in at least one organic solvent selected from the group consisting of an organic solvent having 2 or more and 8 or less carbon atoms, and a method for producing a carbamic acid ester or a urea derivative using the carbamic acid salt.

A method for producing a carbamic acid salt, including contacting a carbon dioxide-containing mixed gas having a partial pressure of carbon dioxide of 0.001 atm or more and less than 1 atm with an amino group-containing organic compound in the presence of a base in at least one organic solvent selected from the group consisting of an organic solvent having 2 or more and 8 or less carbon atoms, and a method for producing a carbamic acid ester or a urea derivative using the carbamic acid salt.

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.

The present invention relates to: a derivative in which glutamate-urea-Lysine (GUL) and isonitrile are linked by a linker; a radioisotope labeled compound comprising the derivative; and a pharmaceutical composition for treating and diagnosing prostate cancer, containing the derivative as an active ingredient. A derivative according to the present invention has high binding capacity for PSMA, which is expressed in prostate cancer, by acting as a multi-ligand through the binding of three or six derivatives to one atom of technetium or rhenium, has excellent stability in human serum when administered in vivo, and is excreted into the kidney rather than the hepatobiliary tract because of high water solubility so that a clear image of a prostate cancer tumor site can be obtained, and thus the present invention can be effectively usable as a pharmaceutical composition for treating or diagnosing prostate cancer.